We Claim:

1. Aldose reductase inhibitor of the formula I or a pharmaceutically acceptable derivative thereof.



I

2. An acid or base addition product of the compound of claim 1
3. A pharmaceutical preparation containing an effective amount of the compound of Claim 1 and one or more pharmaceutically acceptable excipients.
4. Aldose reductase inhibitor as claimed in claim 1 wherein said inhibitor is a rat lens aldose reductase inhibitor.
5. Aldose reductase inhibitor as claimed in claim 1 wherein the aldose reductase inhibitor of formula I is 2, 6, dihydroxy, 8, hexoxy, 1, 4, naphthaquinone.
6. A process for the isolation of a novel aldose reductase inhibitor of the formula I below



I

the process comprising culturing *Aspergillus niger* CFR 1046 and isolating said aldose reductase inhibitor.

7. A process as claimed in claim 6 wherein the aldose reductase inhibitor isolated from *Aspergillus niger* CFR 1046 is 2, 6, dihydroxy, 8, hexoxy, 1, 4, naphthaquinone.
8. A process as claimed in claim 6 wherein the aldose reductase inhibitory compound of formula I is isolated from *Aspergillus niger* CFR 1046 by fermentation.
9. A process as claimed in claim 6 wherein naphthaquinone is isolated from fermentates of *Aspergillus niger* CFR 1046 by solvent extraction.

10. A process as claimed in claim 6 wherein naphthaquinone is isolated from fermentates of *Aspergillus niger* CFR 1046 by column chromatography.
11. A process as claimed in claim 6 wherein naphthaquinone is isolated from fermentates of *Aspergillus niger* CFR 1046 by crystallization.
12. A process as claimed in claim 6 wherein the compound of formula I is extracted from *Aspergillus niger* CFR 1046 from fermented potato dextrose broth using ethyl acetate solvent followed by column chromatography and crystallization.
13. A process as claimed in claim 6 wherein the compound of formula I isolated from *Aspergillus niger* CFR 1046 is converted to a pharmaceutically acceptable derivative.
14. A process as claimed in claim 13 wherein the pharmaceutically acceptable derivative comprises acid or base addition products such as salts of this compound are also useful.
15. A process as claimed in claim 14 wherein the addition products contain hydrochloride, hydrobromide, sulfate, sodium, potassium, calcium and the like ions.